产品活性： Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

The ARMANI trial, a phase 3 multicentre study reported by Giovanni Randon and colleagues,1 investigates the effect of switch ...

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

A significant advance in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A ...

With eyes on larger market opportunities in HER2-positive stomach cancer and breast cancer, Jazz has put Ziihera’s peak annual sales potential at more than $2 billion, CEO Bruce Cozadd told ...

Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with ...

Background: Variable rates of HER2 protein overexpression ... in patients with HER2-positive (fluorescence in situ hybridization [FISH] positive) ovarian cancer progressing under taxane ...